Latest Insider Transactions at Staar Surgical CO (STAA)
This section provides a real-time view of insider transactions for Staar Surgical CO (STAA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of STAAR SURGICAL CO to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of STAAR SURGICAL CO's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 19
2021
|
Stephen C Farrell President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-46.26%
|
$600,000
$120.0 P/Share
|
|
May 19
2021
|
Stephen C Farrell President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+31.63%
|
$25,000
$5.54 P/Share
|
|
May 17
2021
|
Stephen C Farrell President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,328
-47.84%
|
$602,064
$113.87 P/Share
|
|
May 17
2021
|
Stephen C Farrell President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,328
+32.36%
|
$37,296
$7.14 P/Share
|
|
May 12
2021
|
Graydon C. Hansen Sr. VP, Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
954
+3.24%
|
$25,758
$27.31 P/Share
|
|
May 12
2021
|
Graydon C. Hansen Sr. VP, Global Operations |
SELL
Open market or private sale
|
Direct |
5,531
-38.47%
|
$608,410
$110.74 P/Share
|
|
May 11
2021
|
Graydon C. Hansen Sr. VP, Global Operations |
SELL
Open market or private sale
|
Direct |
11,075
-43.51%
|
$1,229,325
$111.61 P/Share
|
|
May 11
2021
|
Graydon C. Hansen Sr. VP, Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
11,075
+17.31%
|
$343,325
$31.76 P/Share
|
|
May 11
2021
|
Caren L Mason President & CEO |
SELL
Open market or private sale
|
Direct |
53,500
-45.78%
|
$5,885,000
$110.7 P/Share
|
|
May 11
2021
|
Caren L Mason President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,500
+31.4%
|
$374,500
$7.76 P/Share
|
|
May 10
2021
|
James E Francese Sr. VP, Comm. Ops., NA, APAC |
SELL
Open market or private sale
|
Direct |
11,583
-18.04%
|
$1,447,875
$125.72 P/Share
|
|
May 10
2021
|
James E Francese Sr. VP, Comm. Ops., NA, APAC |
BUY
Exercise of conversion of derivative security
|
Direct |
11,583
+8.29%
|
$81,081
$7.44 P/Share
|
|
May 10
2021
|
Jon K. Hayashida VP, Global Clinical, Medical |
SELL
Open market or private sale
|
Direct |
12,109
-26.84%
|
$1,501,516
$124.67 P/Share
|
|
May 10
2021
|
Jon K. Hayashida VP, Global Clinical, Medical |
BUY
Exercise of conversion of derivative security
|
Direct |
18,719
+18.69%
|
$505,413
$27.37 P/Share
|
|
May 10
2021
|
Keith Holliday Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
8,874
-28.09%
|
$1,109,250
$125.83 P/Share
|
|
May 10
2021
|
Caren L Mason President & CEO |
SELL
Open market or private sale
|
Direct |
53,500
-45.78%
|
$6,366,500
$119.88 P/Share
|
|
May 10
2021
|
Caren L Mason President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,500
+31.4%
|
$374,500
$7.76 P/Share
|
|
Apr 26
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Apr 26
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
43,383
-0.46%
|
$5,856,705
$135.3 P/Share
|
|
Apr 23
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Apr 23
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
53,854
-0.57%
|
$7,162,582
$133.51 P/Share
|
|
Apr 22
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Apr 22
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
20,669
-0.22%
|
$2,686,970
$130.34 P/Share
|
|
Apr 01
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Bona fide gift
|
Indirect |
0
|
-
|
|
Apr 01
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
100,000
-1.05%
|
-
|
|
Mar 22
2021
|
James E Francese Sr. VP, Comm. Ops., NA, APAC |
SELL
Open market or private sale
|
Direct |
922
-1.72%
|
$88,512
$96.37 P/Share
|
|
Mar 22
2021
|
Samuel J Gesten Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,032
-2.37%
|
$99,072
$96.37 P/Share
|
|
Mar 22
2021
|
Jon K. Hayashida VP, Global Clinical, Medical |
SELL
Open market or private sale
|
Direct |
1,103
-10.22%
|
$105,888
$96.37 P/Share
|
|
Mar 16
2021
|
Scott D Barnes Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,664
-11.56%
|
$253,080
$95.0 P/Share
|
|
Mar 16
2021
|
Scott D Barnes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,664
+10.36%
|
$39,960
$15.25 P/Share
|
|
Mar 12
2021
|
James E Francese Sr. VP, Comm. Ops., NA, APAC |
BUY
Exercise of conversion of derivative security
|
Direct |
2,169
+3.89%
|
-
|
|
Mar 12
2021
|
Samuel J Gesten Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,430
+5.28%
|
-
|
|
Mar 12
2021
|
Keith Holliday Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,471
+7.25%
|
-
|
|
Mar 12
2021
|
Caren L Mason President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,363
+23.4%
|
-
|
|
Mar 12
2021
|
Patrick F. Williams Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,513
+7.03%
|
-
|
|
Mar 12
2021
|
Scott D Barnes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,936
+11.18%
|
-
|
|
Mar 11
2021
|
Scott D Barnes Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,665
-11.56%
|
$245,180
$92.0 P/Share
|
|
Mar 11
2021
|
Scott D Barnes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,665
+10.36%
|
$39,975
$15.25 P/Share
|
|
Mar 09
2021
|
Scott D Barnes Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,333
-14.21%
|
$645,304
$88.87 P/Share
|
|
Mar 09
2021
|
Scott D Barnes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,333
+8.18%
|
$197,991
$27.31 P/Share
|
|
Mar 03
2021
|
Caren L Mason President & CEO |
SELL
Open market or private sale
|
Direct |
45,000
-50.55%
|
$4,410,000
$98.32 P/Share
|
|
Mar 03
2021
|
Caren L Mason President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+33.58%
|
$315,000
$7.76 P/Share
|
|
Mar 02
2021
|
Caren L Mason President & CEO |
SELL
Open market or private sale
|
Direct |
45,000
-50.55%
|
$4,635,000
$103.53 P/Share
|
|
Mar 02
2021
|
Caren L Mason President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+33.58%
|
$315,000
$7.76 P/Share
|
|
Mar 01
2021
|
Graydon C. Hansen Sr. VP, Global Operations |
SELL
Open market or private sale
|
Direct |
33,790
-33.63%
|
$3,514,160
$104.1 P/Share
|
|
Mar 01
2021
|
Graydon C. Hansen Sr. VP, Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
26,615
+8.36%
|
$638,760
$24.41 P/Share
|
|
Mar 01
2021
|
Jon K. Hayashida VP, Global Clinical, Medical |
SELL
Open market or private sale
|
Direct |
16,000
-59.71%
|
$1,680,000
$105.43 P/Share
|
|
Mar 01
2021
|
Jon K. Hayashida VP, Global Clinical, Medical |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+37.39%
|
$560,000
$35.98 P/Share
|
|
Mar 01
2021
|
Keith Holliday Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
18,991
-23.65%
|
$1,975,064
$104.33 P/Share
|
|
Mar 01
2021
|
Keith Holliday Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,783
+8.02%
|
$303,226
$22.81 P/Share
|